Article
Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance.
International journal of molecular sciences - 3 Dec 2024
Bortolot Martina, Torresan Sara, De Carlo Elisa, Bertoli Elisa, Stanzione Brigida, Del Conte Alessandro, Spina Michele, Bearz Alessandra
Abstract excerpt
Although rare in non-small cell lung cancer (NSCLC), BRAF mutations present considerable therapeutic challenges. While the use of BRAF and MEK inhibitor combinations has significantly improved survival outcomes in patients with BRAF V600E mutations, no targeted therapies are currently available for class II and III mutations, leaving the optimal treatment strategy and prognosis for these patients uncertain....
Topics
Join the communities discussing this publication.